Endoscopic Retrograde Cholangiopancreatography (ERCP) and Percutaneous Transhepatic Cholangiography (PTC) Devices Market – Trends Forecast Till 2030

Market Snapshot

Market Overview

The global Endoscopic Retrograde Cholangiopancreatography (ERCP) and Percutaneous Transhepatic Cholangiography (PTC) Devices Market size was estimated at USD 493.7 billion in 2023 and is projected to reach USD 785.2 billion in 2030 at a CAGR of 4.1% during the forecast period 2024-2030.

The Endoscopic Retrograde Cholangiopancreatography (ERCP) and Percutaneous Transhepatic Cholangiography (PTC) devices market is poised for significant growth due to several driving factors. ERCP devices utilize a combination of fluoroscopic imaging and luminal endoscopy for diagnosing and treating disorders associated with the pancreaticobiliary system, while PTC is a therapeutic technique that provides visualization of the biliary duct anatomy. Both procedures are crucial in managing conditions such as obstructive jaundice, biliary leaks, and preventing pancreatitis.

The increasing awareness and adoption of ERCP devices are major factors expected to propel market growth. Additionally, the rising incidence of benign tumors of the pancreas and liver, as well as vaginal cancer, has amplified the demand for these diagnostic and therapeutic devices. Awareness programs and initiatives further contribute to market expansion by educating healthcare professionals and patients about the benefits and applications of ERCP and PTC devices.

Cannulas dominate the product type segment within this market, attributed to the growing prevalence of biliary disorders. These devices play a critical role in treating obstructive jaundice and managing biliary leaks, leading to their widespread use. Market reports on ERCP and PTC devices provide comprehensive insights into market scenarios, including market value, growth rate, segmentation, geographical coverage, and major players. They also encompass expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory frameworks.

The COVID-19 pandemic had a significant impact on the ERCP and PTC devices market in 2020 and beyond. The disruption in healthcare services and elective procedures affected the utilization of these devices. However, the market is expected to recover as healthcare systems adapt and elective procedures resume.

ERCP and PTC devices are integral in preventing pancreatitis and draining gallbladder and pancreatic fluids. These devices are placed through ERCP and PTC procedures, ensuring effective treatment and management of biliary and pancreatic conditions. Market models, covering 39 countries, provide epidemiology-based indications with procedure volumes, enhancing data transparency.

The market report on ERCP and PTC devices introduces market definitions, applications, classifications, and specifications. It covers market dynamics, trends, and growth, alongside competitive landscape analysis. The report ensures data validation by research analysts and experts, providing consumers with authentic market information. Additionally, the report tracks the latest developments and advancements in the market.

Delvens Industry Expert's Standpoint

The global Endoscopic Retrograde Cholangiopancreatography (ERCP) and Percutaneous Transhepatic Cholangiography (PTC) devices market is experiencing robust growth, driven by increased awareness and rising incidences of pancreatic, liver, and vaginal cancers. This growth is further bolstered by the dominance of cannulas, which are essential due to the prevalence of biliary disorders. Despite challenges posed by raw material shortages and shipping delays, strategic assessments and effective action plans are helping businesses navigate these issues. Market reports highlight the current environment and provide valuable insights into market dynamics, growth rates, segmentation, and geographical coverage. The market is segmented by product type, application, and end-user, aiding in the identification of key growth areas. Future predictions indicate continued expansion as awareness programs and technological advancements drive demand. The market's recovery post-COVID-19 is expected to gain momentum, with increased utilization of ERCP and PTC devices in treating obstructive jaundice, biliary leaks, and pancreatitis. Enhanced procurement strategies, distributor mapping, commodity analysis, and supply chain risk management are essential for mitigating current challenges and capitalizing on growth opportunities.

Market Portfolio

Key Findings

• On the basis of Product Type, the product type segment, encompassing sphincterotomes, lithotripters, endoscopes, accessories, stents, cannulas, forceps, snares, catheters, guiding wires, balloons, baskets, and others, is crucial for the growth of the ERCP and PTC devices market. Each product type addresses specific clinical needs in diagnosing and treating pancreaticobiliary disorders. Cannulas and stents dominate due to their widespread use in biliary procedures. Advancements and innovations across these diverse product types enhance procedural efficiency, reduce complications, and improve patient outcomes. This comprehensive range of devices ensures a holistic approach to patient care, driving market expansion and adoption globally.

• On the basis of Application, The application segment, including jaundice, stone removal, postoperative or posttraumatic bile leakage, pancreatitis, and others, drives the growth of the ERCP and PTC devices market by addressing a wide array of pancreaticobiliary disorders. Each application highlights the essential role of these devices in managing specific clinical conditions. For instance, the use of ERCP and PTC devices in treating jaundice and stone removal is critical due to the prevalence of these conditions. Additionally, their application in managing bile leakage and pancreatitis ensures comprehensive patient care. This diversity in applications enhances the adoption and demand for these devices, promoting market growth and innovation.

• On the basis of type, the end-user segment, comprising hospitals, specialty clinics, diagnostic laboratories, and others, significantly contributes to the growth of the ERCP and PTC devices market. Hospitals and specialty clinics are primary settings for these procedures, driving demand due to high patient volumes and advanced healthcare infrastructure. Diagnostic laboratories support early detection and diagnosis, increasing the utilization of ERCP and PTC devices. These end-users' continuous adoption of advanced technologies and their role in providing specialized care enhance market penetration. This broad end-user base ensures widespread device application, fostering market expansion and encouraging innovation to meet diverse clinical needs.

• The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America held the largest Endoscopic Retrograde Cholangiopancreatography (ERCP) and Percutaneous Transhepatic Cholangiography (PTC) Devices Market share due to rising product approvals, government and pharmaceutical awareness initiatives, advanced healthcare infrastructure, and high adoption of innovative technologies.

Regional Analysis

North America to Dominate the Market

• North America dominates the endoscopic retrograde cholangiopancreatography (ERCP) and percutaneous transhepatic cholangiography (PTC) devices market due to a surge in product approvals for treatment and increased initiatives by the government and pharmaceutical organizations to raise disease awareness. The region's advanced healthcare infrastructure and high adoption rate of innovative technologies further bolster market growth. These factors, combined with proactive awareness campaigns and strong support from healthcare policies, drive the significant expansion of the ERCP and PTC devices market in North America, ensuring improved patient outcomes and widespread utilization of these diagnostic and therapeutic devices.

Competitive Landscape

• OLYMPUS CORPORATION
• CONMED Corporation
• TeleMed Systems, Inc.
• Boston Scientific Corporation
• Cook
• Merit Medical Systems
• KARL STORZ SE & Co. KG
• Braun Melsungen AG
• BD (Becton, Dickinson and Company)
• FUJIFILM Corporation
• Medtronic
• HOBBS MEDICAL, INC.
• SureCare
• Richard Wolf GmbH
• PENTAX Medical
• Johnson & Johnson
• Stryker Corporation
• Smith & Nephew plc
• Karl Storz Endoscopy-America, Inc.
• Olympus Medical Systems

Recent Developments

• In December 2023, EndoSound and AdaptiveEndo have partnered to develop a single-use EUS/ERCP device. this device aims to overcome challenges of reusable endoscopes, including infection control, sterilization, and access to care, enhancing procedural success and safety.

Reasons to Acquire

• Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.
   
• Gain authentic and granular data access for the Endoscopic Retrograde Cholangiopancreatography (ERCP) and Percutaneous Transhepatic Cholangiography (PTC) Devices Market to understand the trends and the factors involved in changing market situations.
   
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
   
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope